Isosceles Pharmaceuticals Announces First Patient Dosed in Phase I Clinical Trial of IPI201
Novel intravenous anti inflammatory candidate advances Phase I evaluation to assess safety, tolerability, and pharmacokinetics WILMINGTON, NC, UNITED STATES, April 21, 2026 /EINPresswire.com/ -- Isosceles Pharmaceuticals, Inc. ("Isosceles…